MVM Life Science Partners
Series B to Growth venture capital firm · London
MVM Life Science Partners is a Series B to Growth venture capital firm based in London that typically writes $20M–$100M checks in Medical Devices, Diagnostics and Pharmaceuticals. DryPowder has no SEC Form D on file for MVM Life Science Partners as of June 3, 2026. Partners at MVM Life Science Partners include Eric Bednarski and Hugo Harrod (Partner).
Updated · Sources: fund website
- Typical check
- $20M–$100M
- Stages
- Series B–Growth
- Headquarters
- London
Overview
MVM Life Science Partners at a glance
- Stage
- Series B, Series C, Series D, Growth
- Check size
- $20M–$100M
- Sectors
- Medical Devices, Diagnostics, Pharmaceuticals, Digital Health, Health IT, Life Science Tools, Contract Research, Contract Manufacturing
- Headquarters
- London
- Cold inbound
- Warm intro preferred
- Website
- mvm.com
Investment thesis
Partner with best-in-class management teams to bring innovative healthcare products to market that address significant unmet needs in large addressable markets, with clearly differentiated technology and durable competitive protection.
Stated on mvm.comWEBSITE
What sets MVM Life Science Partners apart
- 28 years of investing history since 1997 with 150+ collective years partner experience
- 41 documented successful exits including IPOs and strategic M&A
- Deep healthcare domain expertise with concentrated portfolio approach
- Focus on companies with regulatory moats and clear exit pathways
Recent investments
DryPowder has tracked these recent investments from MVM Life Science Partners: Neurent Medical, Proverum and Avanzanite.
What the portfolio shows
Portfolio 16
Backed: Avanzanite, Ambio, BioProtect + 13 more
Partners
4 partners at MVM Life Science Partners
- Eric Bednarski
Similar funds
Funds like MVM Life Science Partners
Investor lists that include MVM Life Science Partners
FAQ
Questions about MVM Life Science Partners
What does MVM Life Science Partners invest in?
MVM Life Science Partners is a Series B, Series C, Series D, Growth stage Medical Devices, Diagnostics, Pharmaceuticals, Digital Health, Health IT, Life Science Tools, Contract Research, Contract Manufacturing investor, typically writing $20M – $100M checks, primarily investing in US. Their thesis: Partner with best-in-class management teams to bring innovative healthcare products to market that address significant unmet needs in large addressable markets, with clearly differentiated technology and durable competitive protection.
What check size does MVM Life Science Partners write?
MVM Life Science Partners typically writes $20M – $100M checks at the Series B, Series C, Series D, Growth stage in Medical Devices, Diagnostics, Pharmaceuticals, Digital Health, Health IT, Life Science Tools, Contract Research, Contract Manufacturing.
What makes MVM Life Science Partners different from other funds?
MVM Life Science Partners stands out on 4 points: 28 years of investing history since 1997 with 150+ collective years partner experience; 41 documented successful exits including IPOs and strategic M&A; Deep healthcare domain expertise with concentrated portfolio approach; Focus on companies with regulatory moats and clear exit pathways.
What has MVM Life Science Partners invested in recently?
Recent investments DryPowder has tracked from MVM Life Science Partners include Neurent Medical, Proverum, Avanzanite.
How do I reach MVM Life Science Partners?
MVM Life Science Partners does not generally take cold inbound; a warm introduction from a founder or investor the firm knows is the usual path.
Sources
Updated